BellaSeno, a Leipzig, Germany-based regenerative implant company, is sponsoring two clinical trials that will investigate the effects of its resorbable scaffolds for breast and pectus excavatum reconstruction.
The first trial plans to enroll 10 patients with pectus excavatum. The company’s CEO, Mohit Chhaya told Medtech Insight that the study will target “skeletally mature adolescent” patients who require “medically necessary reconstructive procedures
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?